CYTK

CYTK

USD

Cytokinetics Incorporated Common Stock

$61.480+1.180 (1.957%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$60.300

Máximo

$61.480

Mínimo

$60.010

Volumen

1.92M

Fundamentos de la Empresa

Capitalización de Mercado

7.5B

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

2.29M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $29.31Actual $61.480Máximo $64.13

Noticias Relacionadas

Analyst Upgrades

B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90

B. Riley Securities analyst Mayank Mamtani reiterates Cytokinetics with a Buy and raises the price target from $80 to $90.

Ver más
B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90
PR Newswire

Investors in Cytokinetics, Incorporated Should Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights - CYTK

The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of...

Ver más
Investors in Cytokinetics, Incorporated Should Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights - CYTK
GlobeNewswire

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE

Ver más
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
PR Newswire

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27,...

Ver más
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
PR Newswire

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27,...

Ver más
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
GlobeNewswire

Cytokinetics to Participate in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences

PR Newswire

Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.